Suppliers and packagers for generic pharmaceutical drug: METFORMIN HYDROCHLORIDE; SITAGLIPTIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778	NDA	Zydus Pharmaceuticals USA Inc.	70710-1804-6	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-1804-6)	2024-10-31
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778	NDA	Zydus Pharmaceuticals USA Inc.	70710-1805-6	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-1805-6)	2024-10-31
Zydus Lifesciences	ZITUVIMET XR	metformin hydrochloride; sitagliptin	TABLET, EXTENDED RELEASE;ORAL	216778	NDA	Zydus Pharmaceuticals USA Inc.	70710-1806-3	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-1806-3)	2024-10-31

Metformin Hydrochloride and Sitagliptin: Key API Supplier Landscape

Last updated: February 19, 2026

This analysis identifies leading suppliers of Metformin Hydrochloride and Sitagliptin Active Pharmaceutical Ingredients (APIs), examining their operational scale, regulatory standing, and geographical reach. The data supports strategic sourcing and investment decisions within the pharmaceutical sector.

Who are the primary manufacturers of Metformin Hydrochloride API?

Major manufacturers of Metformin Hydrochloride API are concentrated in Asia, primarily China and India, leveraging cost efficiencies and established chemical synthesis capabilities. Key players include companies with significant production volumes and a history of supplying global pharmaceutical markets.

• China: Dominates global Metformin Hydrochloride API production. Manufacturers are characterized by large-scale facilities and adherence to international quality standards.
  • Hebei Jiheng Pharmaceutical Co., Ltd.: Operates substantial manufacturing capacity. Holds U.S. Food and Drug Administration (FDA) Drug Master Files (DMFs) and European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of Suitability (CEPs).
  • Anhui Biochem.-Pharma Co., Ltd.: A significant producer with facilities accredited by multiple international regulatory bodies, including the FDA and EDQM.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.: While known for a broader API portfolio, Huahai is a notable Metformin Hydrochloride supplier with strong regulatory compliance.
  • Sichuan Kelun Pharmaceutical Co., Ltd.: Part of a larger pharmaceutical group, Kelun has integrated API manufacturing capabilities, including for Metformin Hydrochloride.
• India: Holds a significant share of the global Metformin Hydrochloride API market, known for its strong generics industry and competitive pricing.
  • Laurus Labs Limited: A prominent API manufacturer with substantial capacity and a diversified product portfolio. Holds U.S. FDA and EDQM approvals.
  • Divi's Laboratories Limited: A leading API producer globally, Divi's manufactures Metformin Hydrochloride and is known for its stringent quality control and large-scale production. Possesses U.S. FDA and EDQM CEPs.
  • Sun Pharmaceutical Industries Ltd.: As one of the largest generic pharmaceutical companies, Sun Pharma has integrated API manufacturing, supplying its own needs and the external market with Metformin Hydrochloride.
  • Dr. Reddy's Laboratories: A well-established Indian pharmaceutical company with significant API manufacturing operations, including Metformin Hydrochloride. Holds various international regulatory approvals.

The production of Metformin Hydrochloride, a first-line treatment for type 2 diabetes, is a high-volume, cost-sensitive market. Suppliers with robust supply chains, efficient synthesis processes, and strong regulatory dossiers are competitive.

What is the competitive landscape for Sitagliptin API suppliers?

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat type 2 diabetes, presents a more complex API landscape due to its patent status and more intricate synthesis. While originator Merck & Co. holds primary patents, generic API manufacturers are increasingly entering the market as patents expire in various regions.

• Originator & Licensed Manufacturers:
  • Merck & Co. (MSD): The originator of Sitagliptin (Januvia®). While Merck manufactures its own API, it also licenses its technology and supplies to authorized partners for specific markets or finished dosage forms.
• Key Generic API Suppliers: The generic Sitagliptin API market is emerging, with manufacturers primarily in India and China developing non-infringing processes or supplying after patent expiry.
  • Dr. Reddy's Laboratories (India): Has been active in developing generic Sitagliptin and its intermediates. Holds U.S. FDA DMFs for Sitagliptin.
  • Divi's Laboratories Limited (India): Is a significant player in the API space and is involved in the production of complex molecules, including DPP-4 inhibitors.
  • Laurus Labs Limited (India): Has demonstrated capability in producing APIs for diabetes management and is a potential supplier of Sitagliptin API.
  • Sun Pharmaceutical Industries Ltd. (India): With its extensive generics portfolio, Sun Pharma is positioned to be a supplier of Sitagliptin API.
  • Chinese Manufacturers: Several Chinese API companies are developing and producing Sitagliptin API, often focusing on cost-competitiveness. Specific company names may fluctuate as they establish regulatory filings. Examples include companies with established capabilities in chiral synthesis and complex organic chemistry.
    • Jiangsu Hengrui Medicine Co., Ltd.: A large Chinese pharmaceutical company with a strong R&D and manufacturing base, capable of producing complex APIs.
    • Zhejiang Medicine Co., Ltd.: Another significant Chinese producer with a broad range of APIs.

The Sitagliptin API market is characterized by the need for sophisticated synthetic routes, robust impurity profiling, and intellectual property navigation. Suppliers demonstrating advanced chemical synthesis expertise and a strong understanding of patent landscapes are best positioned.

What are the regulatory considerations for Metformin Hydrochloride and Sitagliptin API suppliers?

Suppliers of Metformin Hydrochloride and Sitagliptin APIs must adhere to stringent regulatory requirements set by major health authorities globally. Compliance is critical for market access and patient safety.

• U.S. Food and Drug Administration (FDA):
  • Drug Master Files (DMFs): Manufacturers must file DMFs for APIs, detailing manufacturing processes, quality control, and stability. U.S. DMFs are reviewed by the FDA in conjunction with finished drug product applications.
  • Current Good Manufacturing Practices (cGMP): Facilities are subject to FDA inspection to ensure compliance with cGMP regulations (21 CFR Parts 210 & 211).
  • Site Registration & Inspections: API manufacturing sites require registration with the FDA and are subject to periodic inspections.
• European Directorate for the Quality of Medicines & HealthCare (EDQM):
  • Certificates of Suitability (CEPs): For APIs like Metformin Hydrochloride, CEPs are often required for use in European Union member states. A CEP certifies that the API complies with the European Pharmacopoeia monograph.
  • Inspections: EDQM or national competent authorities conduct inspections to verify cGMP compliance.
• Other National Regulatory Authorities:
  • Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
  • Therapeutic Goods Administration (TGA) in Australia.
  • Health Canada.
  • National Medical Products Administration (NMPA) in China.
  • Central Drugs Standard Control Organisation (CDSCO) in India.

Regulatory compliance involves not only initial approval but ongoing quality assurance, process validation, and change control management. For Sitagliptin, specific attention is paid to control of genotoxic impurities and polymorphic forms.

How do geographical locations impact API sourcing strategies?

The geographical distribution of API suppliers influences sourcing strategies based on factors such as cost, lead times, regulatory environment, and geopolitical stability.

• Asia (China and India):
  • Strengths: Typically offer lower manufacturing costs due to labor and operational efficiencies. Possess extensive chemical synthesis infrastructure and a large pool of skilled labor. High production volumes are achievable.
  • Considerations: Potential for longer lead times due to international shipping. Geopolitical risks and trade policies can impact supply chain stability. Quality control can vary, necessitating rigorous vendor qualification.
• Europe and North America:
  • Strengths: Often perceived as having higher quality standards and robust regulatory oversight. Shorter lead times for regional pharmaceutical manufacturers. Strong intellectual property protection.
  • Considerations: Higher manufacturing costs compared to Asian suppliers. Production volumes may be smaller for certain generic APIs.

A diversified sourcing strategy, utilizing suppliers from multiple regions, can mitigate risks associated with supply chain disruptions, price volatility, and geopolitical events. For critical APIs like Metformin Hydrochloride and Sitagliptin, dual sourcing from different geographical locations is a common risk management practice.

What are the key differentiators for API suppliers?

Several factors differentiate API suppliers beyond price and basic compliance. These differentiators are crucial for securing reliable, high-quality supply.

• Manufacturing Capacity & Scalability: The ability to consistently produce large volumes of API to meet market demand is essential, particularly for high-volume drugs like Metformin Hydrochloride.
• Quality Management Systems: Robust Quality Management Systems (QMS) that exceed minimum cGMP requirements, including strong analytical capabilities, process validation, and deviation management, are critical.
• Regulatory Track Record: A history of successful FDA, EDQM, and other major health authority inspections, along with a significant number of approved DMFs and CEPs, indicates a reliable supplier.
• Supply Chain Security & Transparency: Verifiable control over raw material sourcing, intermediate manufacturing, and logistics enhances supply chain resilience and transparency.
• Intellectual Property (IP) Navigation: For complex APIs like Sitagliptin, the ability to develop non-infringing synthetic routes and manage patent landscapes is a significant advantage.
• Technical Expertise & R&D Capabilities: Advanced capabilities in process chemistry, impurity profiling, and analytical method development enable suppliers to optimize production and address complex quality challenges.
• Environmental, Social, and Governance (ESG) Practices: Increasing emphasis on sustainable manufacturing, ethical labor practices, and corporate responsibility is becoming a factor in supplier selection.

Suppliers demonstrating strength across these differentiators are better positioned to forge long-term partnerships and support the development and commercialization of pharmaceutical products.

Key Takeaways

• Metformin Hydrochloride API manufacturing is dominated by large-scale producers in China and India, characterized by cost-efficiency and established regulatory compliance.
• Sitagliptin API supply is evolving, with generic manufacturers in India and China emerging post-patent expiry, requiring advanced synthesis and IP navigation.
• Regulatory compliance (FDA DMFs, EDQM CEPs, cGMP) is non-negotiable for both APIs, with ongoing inspections and adherence to evolving standards critical.
• Geographical sourcing strategies should balance cost advantages of Asia with the regulatory assurance and proximity of European and North American suppliers, promoting supply chain resilience.
• Key supplier differentiators include manufacturing scale, robust QMS, regulatory history, IP expertise, and R&D capabilities, extending beyond basic compliance.

Frequently Asked Questions

What is the typical lead time for Metformin Hydrochloride API from Asian suppliers?

Typical lead times can range from 8 to 16 weeks from order confirmation to delivery, depending on supplier inventory, production schedules, and transit logistics.

Are there specific regulatory hurdles for Sitagliptin API manufacturers related to impurities?

Yes, Sitagliptin API manufacturers must pay close attention to the control of process-related impurities and potential genotoxic impurities, which are subject to stringent limits by regulatory authorities.

How often are API manufacturing facilities inspected by the FDA?

FDA inspections are risk-based and can occur at varying frequencies, typically ranging from every 1 to 5 years, depending on the facility's inspection history, product criticality, and observed compliance.

Can a single API supplier reliably meet the global demand for Metformin Hydrochloride?

Given the vast global demand for Metformin Hydrochloride, relying on a single supplier poses significant supply chain risk. Diversified sourcing across multiple reputable manufacturers is recommended.

What is the importance of EDQM CEPs for Sitagliptin API suppliers targeting the European market?

A CEP from EDQM significantly streamlines the regulatory approval process for finished drug products in European Union member states that utilize Sitagliptin API, demonstrating compliance with European Pharmacopoeia standards.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep [3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations [4] World Health Organization. (2015). Good manufacturing practices for pharmaceutical products: main principles. Retrieved from https://www.who.int/teams/regulation-prequalification/standards/good-manufacturing-practices [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Quality Guidelines. Retrieved from https://www.ich.org/page/quality-guidelines